Y-Intercept (HK)’s Vertex Pharmaceuticals VRTX Stock Holding History

Y-Intercept (HK)’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.11M	Sell	8,281 -27,548	-77%	-$12.2M	0.08%	347
2026 Q1	$16M	Buy	+35,829	New	+$16.7M	0.3%	41
2025 Q4	–	Sell	-27,770	Closed	-$10.9M	–	2020
2025 Q3	$10.9M	Buy	+27,770	New	+$11.6M	0.26%	59
2025 Q1	–	Sell	-5,385	Closed	-$2.17M	–	1641
2024 Q4	$2.17M	Buy	+5,385	New	+$2.5M	0.14%	187
2024 Q3	–	Sell	-4,683	Closed	-$2.2M	–	1849
2024 Q2	$2.2M	Buy	+4,683	New	+$2.03M	0.12%	224
2023 Q1	–	Sell	-9,719	Closed	-$2.81M	–	1570
2022 Q4	$2.81M	Buy	+9,719	New	+$2.96M	0.41%	22
2022 Q1	–	Sell	-7,996	Closed	-$1.76M	–	981
2021 Q4	$1.76M	Buy	+7,996	New	+$1.55M	0.42%	45
2021 Q2	–	Sell	-2,579	Closed	-$549K	–	932
2021 Q1	$549K	Buy	+2,579	New	+$566K	0.15%	231

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

CTB

Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

PensionDanmark Copenhagen O, Denmark $12B AUM

BIAS

Beacon Investment Advisory Services Morristown, New Jersey $2.69B AUM 35.07% 1-Year Est. Return

Y-Intercept (HK)'s VRTX Position: Q2 2026 in Review

Y-Intercept (HK) reduced its Vertex Pharmaceuticals (VRTX) stake by 77% in Q2 2026, selling an estimated $12.2M and leaving 8,281 shares worth $4.11M. The position accounts for 0.08% of the portfolio, ranked #347.

Y-Intercept (HK) first reported a position in VRTX in Q1 2021 and has held it in 8 quarters since. The position peaked at $16M in Q1 2026. 252 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Y-Intercept (HK) held 8,281 shares of Vertex Pharmaceuticals worth $4.11M as of Q2 2026.
Y-Intercept (HK) sold 27,548 Vertex Pharmaceuticals shares in Q2 2026, an estimated $12.2M.
Vertex Pharmaceuticals made up 0.08% of Y-Intercept (HK)'s portfolio in Q2 2026, its #347 holding.
Y-Intercept (HK) first reported a position in Vertex Pharmaceuticals in Q1 2021 and has held it in 8 quarters since.
Y-Intercept (HK)'s Vertex Pharmaceuticals position peaked at $16M in Q1 2026.
252 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.